Table 1.
Patient’s characteristics
| Total | RJH | IPC | P | |
|---|---|---|---|---|
| No. of patients | 47 | 27 | 20 | 0.22 |
| Sex: Male/female | 17/30 | 11/16 | 6/14 | 0.18 |
| Age: median (range) | 42(16–62) | 34 (16–60) | 44 (26–62) | 0.001 |
| Disease stage | ||||
| Induction failure/early relapse | 23/1 | 14/1 | 9/0 | 0.47 |
| Relapse/refractory | 23 | 12 | 11 | |
| Cytogenetic/molecular | 0.045 | |||
| Favorable/intermediate/poor/not evaluable | 2/18/19/8 | 1/9/9/8 | 1/9/10/0 | |
| Previous chemotherapy median (range) | 3(1–10) | 4(2–10) | 2(1–3) | <0.001 |
| WBC (x109/L) | 3.0 | 4.4 | 3.0 | 0.27 |
| Median (range) | (0.3–44) | (0.3–11.1) | (0.7–28.0) | |
| Circulating blast (positive/negative) | 28/19 | 17/10 | 11/9 | 0.58 |
| BM blast: median (range) | 35%(1–90) | 56%(1–90) | 17.5%(4–79) | 0.01 |
| Donor type | ||||
| MSD/MUD/Haplo | 13/16/16 | 8/11/8 | 5/7/8 | 0.76 |
| aGvHD prophylaxis | ||||
| CSA + MTX + MMF ± ATG/PT-Cy + CSA ± MMF | 27/20 | 27/0 | 0/20 | <0.001 |
| DLI post HSCT (yes/no) | 13/34 | 2/25 | 11/9 | <0.001 |
RJH Rui Jin Hospital, IPC Institut Paoli-Calmettes, BM bone marrow, MSD matched sibling donor, MUD matched unrelated donor, Haplo haplo-identical donor, aGvHD acute graft-versus-host disease, CsA cyclosporine A, MTX methotrexate, MMF mycophenolate mofetil, ATG anti-thymocyte globulin, PT-Cy posttransplant cyclophosphamide, DLI donor lymphocyte infusion